Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

MLA

Luo, Feng Roger, et al. “Identification and Validation of Phospho-SRC, a Novel and Potential Pharmacodynamic Biomarker for Dasatinib (SPRYCEL), a Multi-Targeted Kinase Inhibitor.” Cancer Chemotherapy and Pharmacology, vol. 62, no. 6, Nov. 2008, pp. 1065–74. EBSCOhost, https://doi.org/10.1007/s00280-008-0699-5.

APA

Luo, F. R., Barrett, Y. C., Yang, Z., Camuso, A., McGlinchey, K., Wen, M.-L., Smykla, R., Fager, K., Wild, R., Palme, H., Galbraith, S., Blackwood-Chirchir, A., & Lee, F. Y. (2008). Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemotherapy and Pharmacology, 62(6), 1065–1074. https://doi.org/10.1007/s00280-008-0699-5

Chicago

Luo, Feng Roger, Yu Chen Barrett, Zheng Yang, Amy Camuso, Kelly McGlinchey, Mei-Li Wen, Richard Smykla, et al. 2008. “Identification and Validation of Phospho-SRC, a Novel and Potential Pharmacodynamic Biomarker for Dasatinib (SPRYCEL), a Multi-Targeted Kinase Inhibitor.” Cancer Chemotherapy and Pharmacology 62 (6): 1065–74. doi:10.1007/s00280-008-0699-5.